Share Name Share Symbol Market Type Share ISIN Share Description
Omega Dia LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.375p -2.07% 17.75p 17.50p 18.00p 18.125p 17.75p 18.125p 4,508.00 12:39:17
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 12.7 0.7 0.5 35.5 19.30

Omega Diagnostics (ODX) Latest News

More Omega Diagnostics News
Omega Diagnostics Takeover Rumours

Omega Diagnostics (ODX) Share Charts

1 Year Omega Diagnostics Chart

1 Year Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

Intraday Omega Diagnostics Chart

Intraday Omega Diagnostics Chart

Omega Diagnostics (ODX) Discussions and Chat

Omega Diagnostics Forums and Chat

Date Time Title Posts
20/1/201710:34Omega Diagnostics1,498.00

Add a New Thread

Omega Diagnostics (ODX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
19/01/2017 16:26:4217.958,0001,436.00O
View all Omega Diagnostics trades in real-time

Omega Diagnostics (ODX) Top Chat Posts

Omega Diagnostics Daily Update: Omega Dia is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker ODX. The last closing price for Omega Diagnostics was 18.13p.
Omega Dia has a 4 week average price of 18.06p and a 12 week average price of 17.77p.
The 1 year high share price is 20.75p while the 1 year low share price is currently 13.88p.
There are currently 108,745,669 shares in issue and the average daily traded volume is 52,043 shares. The market capitalisation of Omega Dia is £19,302,356.25.
hyperboreus: Another sizeable delayed BUY at 18.1p today in addition to the one on Friday (18.11p) Share price in limbo at the moment awaiting news one way or another on the IDH situation it would appear.
hyperboreus: Interesting 30 mins or so researching Mr Sneller, his current holdings as far as I am aware are: Bango (BGO) 3,000,000 shares = 4.68% Bioquell (BQE) minimal holding Hayward Tyler(HAYT) 3,625,000 shares = 6.55% Omega (ODX) 11,453,488 shares = 10.53% Plant Impact (PIM) 2,493,000 shares = under 3% Prior to 26 October 2016 he held 2,320,000 shares in Cyprotex a Bioscience operation who received a recommended offer of 160p from Evotec, a GERMAN 'Drug Discovery' operation. Since he pocketed £3,712,000 from the takeover of Cyprotex he appears to have acquired a significant stake in Hayward Tyler and continued to increase his holding in Omega. What is really interesting is that Sneller started to build his stake in Cyprotex in 2009 when the share price was around 5p and incidentally was still around those levels in early 2014. PATIENCE IS CLEARLY HIS WATCHWORD!
hyperboreus: Just to add my two penneth worth here regarding attracting a wider share base, I am not at all bothered by other investor's ignorance in Omega at the moment as I personally added to my holding when the share price dipped below 15p and have recently added upto and around the 18p mark. A lot of the smaller investors will jump on board once it is tipped by the likes of SCSW by which time the price will likely be a good deal higher. From my own personal experience investing in smaller companies requires a good deal of patience, self-confidence and an element of good luck. 12 months ago I was virtually the only poster on the ALT board and just look what has happened there 😛
barrywhit: There just seems no interest in the shares apart from a few large holders and us LTH's. Perhaps they need to do a company presentation to attract a wider share base. Because I'm not sure what will ignite the share price apart from a positive CD4 update.....
barrywhit: longshanks, Polar Capital reduced their holding by 400k from 5% to 3.88% in IDH, but IDH are starting to show some increase in share price, so interesting times for IDH and hopefully ODX......
longshanks: And don't forget they all have "shareholder friendly" options that only vest once the share price reaches 50p.It looks to me like we are reaching a prime price point. Selling into the last "surge" has so far failed to defeat the rise and whilst I'm looking for 20p as the first sign that we are starting a bull run, I am confident the upside now is far ahead of any downside risk.
rivaldo: Encouraging comments here from the FD and MD (Andrew Shepherd). I wonder what the share price will be once the market latches on to the possibility of $115m of revenues from CD4 kits. Just a fraction of that would do wonders for a small cap like ODX.... Http:// Extract: "Kieron Harbinson finance director: “It’s clearly early days; there needs to be an engagement programme with IDS. We will examine all options, but the fact they have made an approach tells us they recognise the value of the asset we’ve created over the past five years. Until there is clarification we will continue to develop the range of tests.” In October Omega CE-Marked its allergy launch panel, comprising 41 allergens which are capable of being run on IDS’ iSYS instrument. There are plans to grow this number to 120 – for which it received a £1.8m grant from Scottish Enterprise in August. The company has also made “significant progress” with its Visitect CD4 product. After lengthy delays, the tool for determining in the field whether HIV patients require retroviral drug treatment, has now been tested in more than 500 patients in three UK hospitals. Production will now commence on 10,000 devices for external field trials in India, France and sub-Saharan Africa. “A lot of data is going to come from these studies in the first calendar quarter,” said Mr Shepherd. “It takes some time to verify all that data so we’re expecting at the moment we’ll be launching the product with a CE-Marking in the second half of calendar 2017.” The World Health Organisation has estimated that around 22 to 23 million CD4 kits could be required per year, retailing at $5. “There is a significant market out there and everyone we speak to in this global health arena is saying we need this product, we need it desperately, right down at field level,” said Mr Shepherd. The company’s allergy and autoimmune division saw sales grow 11 per cent to £1.76m, while its infectious disease division grew sales by one per cent to £1.23m. In this area its Pune site in India is now producing Malaria point of care kits, which Mr Shepherd said would drive growth in that division. “We’ve invested £1m in Pune and it’s now time for that to start generating a commercial return,” said Mr Harbison. “Malaria will be first but we’ve got a pipeline of future products to come of that facility.” Its food intolerance division grew 15 per cent to £3.84m, driven by ongoing success in the US. Omega also noted growth in Middle East and India, where sales grew 46 per cent. "
rivaldo: Nice reminder barrywhit. We know from the update that the results will be good, so we may well see a move upwards in the share price in reaction. Hopefully there will be more news on CD4 and Allersys, though there was a pretty full update on 17th October, so I'm not sure there'll be much more to say since then.
rivaldo: Nice start to the week - anything up (apart from the share price!)?
gary38: Omega Diagnostics Group PLC Holding(s) in CompanyIntraday Omega Diagnostics ChartIntraday Omega Diagnostics Chart09/06/2016 8:07amUK Regulatory (RNS & others)TIDMODXRNS Number : 7240AOmega Diagnostics Group PLC09 June 2016TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) --------------------------------------------------------------------------------------------- 1. Identity of the issuer or Omega Diagnostics Group the underlying issuer plc of existing shares to which voting rights are attached: (ii) --------------------------------------------------------------- ---------------------------- 2 Reason for the notification (please tick the appropriate box or boxes): --------------------------------------------------------------------------------------------- An acquisition or disposal of voting rights X ------------------------------------------------------------------- ------------------------ An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached ------------------------------------------------------------------- ------------------------ An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments ------------------------------------------------------------------- ------------------------ An event changing the breakdown of voting rights ------------------------------------------------------------------- ------------------------ Other (please specify): --------------------------------------------------------- -------- ------------------------ 3. Full name of person(s) Richard Edgar Sneller subject to the notification obligation: (iii) ----------------------------------------------------------- -------------------------------- 4. Full name of shareholder(s) (if different from 3.):(iv) ----------------------------------------------------------- -------------------------------- 5. Date of the transaction 8(th) June 2016 and date on which the threshold is crossed or reached: (v) ----------------------------------------------------------- -------------------------------- 6. Date on which issuer 8(th) June 2016 notified: ----------------------------------------------------------- -------------------------------- 7. Threshold(s) that is/are >6% crossed or reached: (vi, vii) ----------------------------------------------------------- -------------------------------- 8. Notified details: ---------------------------------------------------------------------------------------------------------------------- A: Voting rights attached to shares (viii, ix)---------------------------------------------------------------------------------------------------------------------- Class/type Situation previous Resulting situation after the of to the triggering triggering transaction shares transaction if possible using the ISIN CODE ------------- -------------------------------- --------------------------------------------------------------------- Number Number Number Number of % of voting of of of shares voting rights (x) Shares Voting rights Rights ------------- --------------- --------------- -------------- -------------------------- ------------------------- Direct Direct Indirect Direct Indirect (xi) (xii) ------------- ----------- ----------- -------------- ------------ ------------ ------------ ----------- GB00B1VCP282 6,515,000 6,515,000 6,765,000 6,765,000 6.22% ------------- --------------- --------------- -------------- ------------ ------------ ------------ ----------- B: Qualifying Financial Instruments ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Expiration Exercise/ Number of voting % of voting financial date Conversion rights that rights instrument (xiii) Period (xiv) may be acquired if the instrument is exercised/ converted. ----------------- ------------- ------------------------------- ---------------------------- --------------------- C: Financial Instruments with similar economic effect to Qualifying Financial Instruments (xv, xvi) ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Exercise Expiration Exercise/ Number of voting % of voting financial price date Conversion rights instrument rights (xix, instrument (xvii) period refers to xx) (xviii) --------------- ------------- ------------- ---------------- ---------------------------- ----------------------- Nominal Delta --------------- ------------- ------------- ---------------- ---------------------------- ------------ --------- Total (A+B+C) ---------------------------------------------------------------------------------------------------------------------- Number of voting rights Percentage of voting rights ------------------------------------------------- ------------------------------------------------------------------- 6,765,000 6.22% ------------------------------------------------- ------------------------------------------------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: (xxi) ------------------------------------------------------------------------------- Proxy Voting: ------------------------------------------------------------------------------- 10. Name of the proxy holder: ------------------------------------------------------------- ---------------- 11. Number of voting rights proxy holder will cease to hold: ------------------------------------------------------------- ---------------- 12. Date on which proxy holder will cease to hold voting rights: ------------------------------------------------------------- ---------------- 13. Additional information: ------------------------------------------------------------- ---------------- 14. Contact name: Richard Sneller ------------------------------------------------------------- ---------------- 15. Contact telephone number: 0131 275 2198 ------------------------------------------------------------- ---------------- This information is provided by RNSThe company news service from the London Stock ExchangeENDHOLUKRWRNSANRRR(END) Dow Jones NewswiresJune 09, 2016 04:07 ET (08:07 GMT)Omega Diagnostics Share Price TodayOmega Diagnostics Share Price ChartOmega Diagnostics Share ChatOmega Diagnostics NewsOmega Diagnostics Share Price HistoryOmega Diagnostics DividendOmega Diagnostics TradesOmega Diagnostics Level 2Add Omega Diagnostics to WatchlistAdd Omega Diagnostics to your PortfolioOmega Diagnostics Share Price AlertSwitch to Desktop View By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & ConditionsShare and Investment Glossary Investment Warning Copyright © 1999 - 2016 Cookie and Privacy Policy
Omega Diagnostics share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170120 16:07:39